Interim Report January–June 2020
ChromoGenics adopts a position for accelerated growthQ2 2020 · Net sales for the period amounted to SEK 4.0 (12.5) million, and earnings amounted to SEK -18.9 (-18.3) million, which corresponds to earnings per share of SEK - 0.03 (-0.11). · ChromoGenics continued to be affected by the coronavirus pandemic during the second quarter, which resulted in delayed orders from the company’s customers. Order intake and invoicing have been postponed in 2020. Net sales in the current year are therefore expected to be lower than net sales in 2019. An action program to reduce the company’s